Magazine Article | February 1, 2022

Put Quality Ahead Of Cost In Adverse Event Reporting Automation

Source: Life Science Leader

By John Price, Ph.D.

In 2021, quality became the primary criterion for automating pharmacovigilance (PV) workloads according to the findings of Arriello’s second annual transatlantic survey into the industry’s PV automation intentions. Barriers to automation persisted, including fear for human jobs, along with validation issues. Life sciences companies’ plans to invest in smart solutions to help handle rising pharmacovigilance workloads may have seen delay due to the pandemic, but there are clear signs that these plans remain a priority.


Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Life Science Leader? Subscribe today.

Subscribe to Life Science Leader X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.


Subscribe to Life Science Leader